CD14 and myocardial infarction: A series of in vivo trials investigating the effect of CD14 blockade on cardiac structure and function were performed, with endpoints assessed at 1, 3, 7, 21, and 28 days post-STEMI, and mechanistic studies (ie, cardiac cell sorting, single-cell RNA sequencing [scRNAseq], and proteomics) at earlier timepoints (1 and/or 3 days post-MI).